BLOG

Researchers examined two cohorts of patients who received CD19-directed CAR-T

GC012F (Gracell Biotechnologies) is an autologous, genetically engineered, bispecific CAR-T

Many drugs cannot cross the blood-brain barrier (BBB), which also

GC012F is an autologous, genetically engineered, bispecific CAR-T that targets

Jin-Soo Kim’s team has discovered how to edit the mitochondrial

Researchers have shown that a synthetic IL-9 receptor allows anti-cancer

A major drawback of CRISPR-Cas9-mediated genome editing is that not

Genetically modified immune cells successfully target specific cancer cells that

Breakthrough findings were presented at the 2022 ASCO Annual Meeting